Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DAD65R
|
|||
Drug Name |
RP-3500
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | |
Company |
Repare Therapeutics
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Serine/threonine-protein kinase ATR (FRP1) | Target Info | Inhibitor | [2] |
KEGG Pathway | Fanconi anemia pathway | |||
Cell cycle | ||||
p53 signaling pathway | ||||
HTLV-I infection | ||||
Panther Pathway | p53 pathway | |||
p53 pathway feedback loops 2 | ||||
Pathway Interaction Database | Fanconi anemia pathway | |||
ATR signaling pathway | ||||
Signaling events mediated by TCPTP | ||||
Circadian rhythm pathway | ||||
BARD1 signaling events | ||||
p53 pathway | ||||
Reactome | Meiotic synapsis | |||
Activation of ATR in response to replication stress | ||||
Regulation of HSF1-mediated heat shock response | ||||
HDR through Single Strand Annealing (SSA) | ||||
Processing of DNA double-strand break ends | ||||
Presynaptic phase of homologous DNA pairing and strand exchange | ||||
G2/M DNA damage checkpoint | ||||
WikiPathways | DNA Damage Response | |||
Meiotic Synapsis | ||||
Prostate Cancer | ||||
Integrated Breast Cancer Pathway | ||||
Integrated Cancer pathway | ||||
Cell Cycle | ||||
Cell Cycle Checkpoints | ||||
miRNA Regulation of DNA Damage Response |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04497116) Study of RP-3500 in Advanced Solid Tumors. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of Repare Therapeutics. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.